Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ)
CNY 4.19
(-0.48%)
CNY 4.19
(-0.48%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.08 Billion CNY | -23.72% |
| 2022 | 2.72 Billion CNY | -2.57% |
| 2021 | 2.8 Billion CNY | -37.69% |
| 2020 | 4.49 Billion CNY | -16.34% |
| 2019 | 5.37 Billion CNY | -5.54% |
| 2018 | 5.68 Billion CNY | 9.42% |
| 2017 | 5.19 Billion CNY | 20.51% |
| 2016 | 4.31 Billion CNY | 12.41% |
| 2015 | 3.83 Billion CNY | 38.71% |
| 2014 | 2.76 Billion CNY | 513.59% |
| 2013 | 450.69 Million CNY | 44.46% |
| 2012 | 311.98 Million CNY | 18.17% |
| 2011 | 264.02 Million CNY | 59.23% |
| 2010 | 165.81 Million CNY | -23.77% |
| 2009 | 217.51 Million CNY | -7.46% |
| 2008 | 235.03 Million CNY | 8.32% |
| 2007 | 216.99 Million CNY | -7.73% |
| 2006 | 235.17 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.79 Billion CNY | -6.59% |
| 2024 Q2 | 1.92 Billion CNY | -1.44% |
| 2024 Q1 | 1.95 Billion CNY | -6.06% |
| 2023 Q1 | 2.76 Billion CNY | 1.29% |
| 2023 Q3 | 2.48 Billion CNY | -3.26% |
| 2023 Q4 | 2.08 Billion CNY | -16.14% |
| 2023 FY | 2.08 Billion CNY | -23.72% |
| 2023 Q2 | 2.56 Billion CNY | -7.18% |
| 2022 Q2 | 2.82 Billion CNY | 7.06% |
| 2022 Q3 | 2.93 Billion CNY | 4.13% |
| 2022 Q4 | 2.72 Billion CNY | -7.14% |
| 2022 Q1 | 2.63 Billion CNY | -5.89% |
| 2022 FY | 2.72 Billion CNY | -2.57% |
| 2021 FY | 2.8 Billion CNY | -37.69% |
| 2021 Q3 | 2.8 Billion CNY | -19.96% |
| 2021 Q1 | 4.41 Billion CNY | -1.84% |
| 2021 Q2 | 3.5 Billion CNY | -20.62% |
| 2021 Q4 | 2.8 Billion CNY | -0.09% |
| 2020 Q1 | 5.37 Billion CNY | -0.0% |
| 2020 FY | 4.49 Billion CNY | -16.34% |
| 2020 Q2 | 4.86 Billion CNY | -9.51% |
| 2020 Q3 | 4.8 Billion CNY | -1.2% |
| 2020 Q4 | 4.49 Billion CNY | -6.42% |
| 2019 FY | 5.37 Billion CNY | -5.54% |
| 2019 Q3 | 5.19 Billion CNY | -0.48% |
| 2019 Q2 | 5.22 Billion CNY | -7.91% |
| 2019 Q1 | 5.66 Billion CNY | -0.3% |
| 2019 Q4 | 5.37 Billion CNY | 3.39% |
| 2018 Q4 | 5.68 Billion CNY | 0.03% |
| 2018 FY | 5.68 Billion CNY | 9.42% |
| 2018 Q1 | 5.24 Billion CNY | 0.94% |
| 2018 Q2 | 5.85 Billion CNY | 11.58% |
| 2018 Q3 | 5.68 Billion CNY | -2.88% |
| 2017 Q4 | 5.19 Billion CNY | 4.52% |
| 2017 FY | 5.19 Billion CNY | 20.51% |
| 2017 Q1 | 4.44 Billion CNY | 3.19% |
| 2017 Q2 | 4.9 Billion CNY | 10.15% |
| 2017 Q3 | 4.97 Billion CNY | 1.43% |
| 2016 FY | 4.31 Billion CNY | 12.41% |
| 2016 Q4 | 4.31 Billion CNY | -2.72% |
| 2016 Q3 | 4.43 Billion CNY | 5.58% |
| 2016 Q2 | 4.19 Billion CNY | 5.83% |
| 2016 Q1 | 3.96 Billion CNY | 3.42% |
| 2015 Q3 | 3.7 Billion CNY | 6.83% |
| 2015 Q1 | 2.96 Billion CNY | 7.28% |
| 2015 FY | 3.83 Billion CNY | 38.71% |
| 2015 Q2 | 3.46 Billion CNY | 16.85% |
| 2015 Q4 | 3.83 Billion CNY | 3.58% |
| 2014 Q4 | 2.76 Billion CNY | 11.55% |
| 2014 Q1 | 1.67 Billion CNY | 271.26% |
| 2014 Q2 | 2.15 Billion CNY | 28.82% |
| 2014 FY | 2.76 Billion CNY | 513.59% |
| 2014 Q3 | 2.47 Billion CNY | 15.02% |
| 2013 Q4 | 450.69 Million CNY | -3.94% |
| 2013 FY | 450.69 Million CNY | 44.46% |
| 2013 Q1 | 307.08 Million CNY | -1.57% |
| 2013 Q2 | 350.07 Million CNY | 14.0% |
| 2013 Q3 | 469.16 Million CNY | 34.02% |
| 2012 FY | 311.98 Million CNY | 18.17% |
| 2012 Q3 | 270.91 Million CNY | 1.38% |
| 2012 Q2 | 267.21 Million CNY | 3.26% |
| 2012 Q4 | 311.98 Million CNY | 15.16% |
| 2012 Q1 | 258.76 Million CNY | -1.99% |
| 2011 Q1 | 182.36 Million CNY | 9.98% |
| 2011 Q3 | 196.16 Million CNY | -2.49% |
| 2011 Q4 | 264.02 Million CNY | 34.59% |
| 2011 FY | 264.02 Million CNY | 59.23% |
| 2011 Q2 | 201.16 Million CNY | 10.31% |
| 2010 Q2 | 199.56 Million CNY | -4.47% |
| 2010 Q3 | 175.12 Million CNY | -12.25% |
| 2010 Q1 | 208.91 Million CNY | -3.95% |
| 2010 Q4 | 165.81 Million CNY | -5.32% |
| 2010 FY | 165.81 Million CNY | -23.77% |
| 2009 FY | 217.51 Million CNY | -7.46% |
| 2009 Q2 | 202.73 Million CNY | 0.0% |
| 2009 Q4 | 217.51 Million CNY | 0.0% |
| 2008 FY | 235.03 Million CNY | 8.32% |
| 2007 FY | 216.99 Million CNY | -7.73% |
| 2006 FY | 235.17 Million CNY | 0.0% |